Bio-Path Holdings

Bio-Path Holdings advances in cancer treatment trials, secures $4M funding. Lead candidate prexigebersen progresses in Phase 2 for AML, explores obesity-related cancers. Pipeline includes BP1001-A for solid tumors, BP1002 for lymphoid malignancies and AML, BP1003 for pancreatic cancer. DNAbilize® technology enhances drug delivery. Strengthened financials support ongoing trials.

DelveInsight's follicular lymphoma pipeline report highlights 50+ companies developing 55+ therapies, including key players like Chia Tai Tianqing Pharmaceutical Group, Incyte Corporation, and others. Promising therapies such as Parsaclisib, TQ-B3525, and Tafasitamab are in various clinical trial phases. Notable events include Incyte's acquisition of tafasitamab rights and Janssen's collaboration with CBMG for CAR-T therapies.

Bio-Path Holdings initiated its obesity program, expanding DNAbilize® technology beyond oncology. The company reported financial results for Q3 2024, including a net loss of $2.1 million, and highlighted recent developments such as the swift enrollment in a Phase 1/1b clinical trial for BP1002 in venetoclax-resistant AML patients and the publication of BP1003's broad anti-tumor effect in Biomedicines.

The T-cell malignancies market is expanding due to increased incidence, treatment advancements, and strategic partnerships. Key companies like Corvus Pharmaceuticals, Bristol-Myers Squibb, and Kymera Therapeutics are developing over 80 pipeline therapies. Notable drugs include Soquelitinib (Phase III), MB 105 (Phase II), and KT-333 (Phase I). Regulatory milestones and positive trial results are driving progress in this field.

Bio-Path Holdings announces publication in 'Biomedicines' on BP1003's broad anti-tumor effect in solid tumors like breast, ovarian, and pancreatic cancer. BP1003 targets STAT3 mRNA, enhancing stability and cellular uptake, potentially improving chemotherapy efficacy in various cancers.